Abstract:Clostridium difficile is a bacterial pathogen that causes serious and potentially fatal inflammatory disease of the colon. One strategy for targeting C. difficile infection is to development treatments that target bacterial virulence. Anti‐virulence strategies to treat C. difficile infection are attractive options to antibiotic therapy because the human microbiota is spared and damage to host tissue is minimized. The Tcd toxins, TcdA and TcdB, are the major virulence factors produced by C. difficile and mediate host cytotoxicity by glucosylating and inactivating Rho family GTPases using UDP‐glucose as a glucosyl donor. Glucosylation of Rho GTPases leads to cell rounding and eventually cell death. We used kinetic isotope effects (KIEs) and transition state theory to solve the transition state structure of the glycosyltransferase domain of TcdB (TcdB‐GTD). This permits the design of transition state analogues which are potent enzyme inhibitors. KIEs compare the chemical steps of enzymatic reaction rates with isotopically labeled substrates and unlabeled substrates and provide critical information on the catalytic mechanism, bond lengths and geometry at the transition state. KIE analysis on the glycohydrolase reaction of TcdB‐GTD supported the formation of a late, dissociative glucocation‐like transition state where positive charge develops on the anomeric carbon. Glucocationic transition states are best mimicked by cationic nitrogen groups at or near the anomeric carbon. Iminosugars contain a nitrogen atom in the sugar ring in place of oxygen and mimic glucocationic transition states. We tested iminosugars for inhibition of TcdB‐GTD and TcdA‐GTD. Isofagomine (Ki TcdB‐GTD = 1.4 µM and Ki TcdA‐GTD = 0.24 µM) and noeuromycin (Ki TcdB‐GTD = 10.6 µM and Ki TcdA‐GTD = 4.7 µM) were the most potent iminosugars identified. Isofagomine and noeuromycin were shown to exhibit an uncompetitive mechanism of inhibition suggesting that both iminosugars act by binding to the enzyme‐UDP complex. Isothermal titration calorimetry experiments with TcdB‐GTD supported this finding where isofagomine and noeuromycin could only bind to TcdB‐GTD in the presence of UDP with Kd = 0.133 µM and Kd = 0.4 µM respectively. In addition, the X‐ray crystal structure of TcdB‐GTD in complex with either Isofagomine or noeuromycin with UDP revealed the formation of an ion‐pair interaction between the cationic nitrogen atom of the iminosugar and the β‐phosphate of UDP. Finally, we confirmed that isofagomine and noeuromycin could prevent Tcd toxin‐induced cytotoxicity of IMR90 cells. Firstly, both iminosugars were able to prevent Tcd toxin‐induced cell rounding as visualized by light microscopy. Secondly, Western blot analysis of Tcd toxin treated IMR90 cell lysates revealed that both isofagomine and noeuromycin could prevent glucosylation of Rac1 by Tcd toxin. Isofagomine and noeuromycin are effective in preventing Tcd toxin action. Transition state analogues against TcdA and TcdB have the potential to be used as treatments for C. difficile infections.

Loratadine is an anti-inflammatory agent against C. difficile toxin B

Modulation of Lactobacillus Rhamnosus GG on the Gut Microbiota and Metabolism in Mice with Clostridioides Difficile Infection

Inflammatory-Dependent Bidirectional Effect of Bile Acids on NLRP3 Inflammasome and Its Role in Ameliorating CPT-11-Induced Colitis.

Exploring the inhibitory potential of the antiarrhythmic drug amiodarone against Clostridioides difficile toxins TcdA and TcdB

<i>Akkermansia muciniphila</i> Ameliorates <i>Clostridioides difficile</i> Infection in Mice by Modulating the Intestinal Microbiome and Metabolites

Loratadine Combats Methicillin-Resistant Staphylococcus aureus by Modulating Virulence, Antibiotic Resistance, and Biofilm Genes

Effect of novel A2A adenosine receptor agonist ATL 313 on Clostridium difficile toxin A-induced murine ileal enteritis

The Compound U18666A Inhibits the Intoxication of Cells by Clostridioides difficile Toxins TcdA and TcdB

Inhibitory Effects of the Lactobacillus rhamnosus GG Effector Protein HM0539 on Inflammatory Response Through the TLR4/MyD88/NF-кB Axis

Loratadine Interacts With MgrA and Inhibits Staphylococcus aureus Virulence and Biofilm Formation

Saccharomyces Boulardii Inhibits Clostridium Difficile Toxin A Binding and Enterotoxicity in Rat Ileum

A Novel Bacteriophage Lysin-Human Defensin Fusion Protein is Effective in Treatment of Clostridioides Difficile Infection in Mice

Bifidobacterium Animalis Subsp. Lactis XLTG11 Improves Antibiotic-Related Diarrhea by Alleviating Inflammation, Enhancing Intestinal Barrier Function and Regulating Intestinal Flora.

Blocking Toxin Function and Modulating the Gut Microbiota: Caffeic Acid and Its Derivatives As Potential Treatments for Clostridioides Difficile Infection

CDBN-YGXZ, a Novel Small-Molecule Drug, Shows Efficacy against <i>Clostridioides difficile</i> Infection and Recurrence in Mouse and Hamster Infection Models

Characterization and development of new anti‐toxins targeting Clostridium difficile

Identification of Tubocapsanolide A as a novel NLRP3 inhibitor for potential treatment of colitis

Bezlotoxumab Therapy for Recurrent Clostridium difficile Infection in an Ulcerative Colitis Patient

Mechanisms of Protection Against Clostridium Difficile Infection by the Monoclonal Antitoxin Antibodies Actoxumab and Bezlotoxumab

Alleviation Effects of Bifidobacterium animalis subsp. lactis XLTG11 on Dextran Sulfate Sodium-Induced Colitis in Mice

Therapeutic Potential of Latilactobacillus Curvatus CCFM1268 in Colitis Treatment: Insights from in Vitro and in Vivo Studies